AtriCure (ATRC) Tops Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts ATRC Hot Sheet
Price: $58.38 -3.93%
Revenue Growth %: +12.6%
Financial Fact:
Income tax expense (benefit): 2K
Today's EPS Names:
OCCI, IPX, ALZN, More
Revenue Growth %: +12.6%
Financial Fact:
Income tax expense (benefit): 2K
Today's EPS Names:
OCCI, IPX, ALZN, More
Join SI Premium – FREE
AtriCure (NASDAQ: ATRC) reported Q2 EPS of ($0.13), $0.04 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $136.1 million versus the consensus estimate of $130.17 million.
GUIDANCE:
AtriCure sees FY2025 EPS of ($0.39)-($0.34), versus the consensus of ($0.51). AtriCure sees FY2025 revenue of $527-533 million, versus the consensus of $523 million.
For earnings history and earnings-related data on AtriCure (ATRC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
- Tempest Therapeutics (TPST) files for 9.53M share offering by selling stockholders
- NeuroSense posts narrower H1 loss, targets Canada drug filing by December
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
